Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 6NET 2Thoracic 1

Conditions

Neuroendocrine Tumors 13Zollinger-Ellison Syndrome 2Vipoma 2Somatostatinoma 2Pheochromocytoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Carcinoma, Medullary 2Carcinoid Tumor 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastrinoma 1Frailty 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Nivolumab 5Ipilimumab 3Everolimus 3lutetium Lu 177 dotatate 2cabozantinib 2atezolizumab 2Temozolomide 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Fluorodeoxyglucose F18 2Etoposide 2Cisplatin 2Capecitabine 2tivozanib 1sintilimab 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1copper dotatate CU-64 1belinostat 1avelumab 1Sunitinib 1Somatostatin 1Drug Therapy 1Copper 1Carboplatin 1CTLA-4 Antigen 1Bevacizumab 164Cu-DOTATATE 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Temozolomide × NET × Clear all
NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
55 enrolled
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Asan Medical Center

Phase 2 Completed
31 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡